Skip to main content

Table 2 Efficacy results at year 4 in the telbivudine-treated Taiwanese population of the GLOBE trial

From: Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

  All ITT patients Patients with HBV DNA level <300 copies/mL at Week 24
Characteristic HBeAg-positive (n = 16) HBeAg-negative (n = 25) HBeAg-positive (n = 7) HBeAg-negative (n = 16)
HBV DNA level     
<300 copies/mL, n (%) 8/16 (50.0) 19/25 (76.0) 7/7 (100.0) 11/16 (78.3)
ALT normalization, n (%) 9/16 (56.3) 20/24 (83.0) 5/7 (71.4) 11/15 (86.4)
HBeAg loss, n (%) 6/16 (37.5) NA 6/7 (85.7) NA
HBeAg seroconversion, n (%) 4/16 (25) NA 4/7 (57.1) NA
Resistance, n (%) 7/16 (43.8) 3/24 (12.5) 0/7 (0.0) 2/23 (8.7)